Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ERN1 | O75460 | 4/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018299 | 0.83 | PRF1 (0.60) | PRF1ALDH1A1APPKDM4EGAA | |
| SCHEMBL2016057 | 0.82 | PRF1 (0.56) | PRF1APPMAPTKMT2ACYP2E1 | |
| SCHEMBL2014491 | 0.81 | PRF1 (0.62) | PRF1ALDH1A1ERN1APPKDM4E | |
| SCHEMBL2015912 | 0.80 | APP (0.54) | PRF1ALDH1A1ERN1APPKDM4E | |
| SCHEMBL20718442 | 0.80 | HPGDS (0.51) | PRF1ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL27108460 | 0.79 | ALDH1A1 (0.55) | PRF1ALDH1A1CA1CA2CA12 | |
| SCHEMBL2015377 | 0.79 | PRF1 (0.56) | PRF1ERN1APPMAPTCYP2E1 | |
| SCHEMBL29906326 | 0.79 | CA1 (0.50) | PRF1ALDH1A1ERN1APPCA1 | |
| SCHEMBL2019176 | 0.78 | PRF1 (0.58) | PRF1ALDH1A1ERN1APPMAPT | |
| SCHEMBL2357473 | 0.78 | PRF1 (0.49) | PRF1ALDH1A1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | GB006 INC (US) | 2020-04-23 | — | — | US | disclosed |
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | GB006 INC (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2018126072-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ADHAERE PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| EP-2176222-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2014-11-05 | — | — | EP | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8598365-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2013-12-03 | — | — | US | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| EP-2176222-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009015877-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | PRF1 4813/4885ALDH1A1 3500/4885ERN1 2227/4885 |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | PRF1 1625/4885ALDH1A1 1070/4885ERN1 2906/4885 |
| US-20120040826-A1 | NOVEL HERBICIDES | DDT, HDHD5, DDC | PRF1 4872/4885ALDH1A1 294/4885ERN1 3645/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | PRF1 4861/4885ALDH1A1 4254/4885ERN1 3244/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | PRF1 4813/4885ALDH1A1 3500/4885ERN1 2227/4885 |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | PRF1 1/4885ALDH1A1 3531/4885ERN1 1616/4885 |
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ITGA1, ITGA4, ITGA2 | PRF1 2326/4885ALDH1A1 1447/4885ERN1 4169/4885 |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | PRF1 4813/4885ALDH1A1 3500/4885ERN1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.